Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - December 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Novemeber 2011. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table Of Contents

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 6
2 Pharmaceuticals and Healthcare, Global, Deal Summary, 8
2.1 Pharmaceuticals and Healthcare, Global, Deals Analysis, November 2011 8
2.2 Pharmaceuticals and Healthcare, Global, Top Deals, November 2011 10
2.2.1 Gilead Sciences To Acquire Pharmasset For $11 Billion 10
2.2.2 Amgen Completes Public Offering Of Senior Notes For $6 Billion 10
2.2.3 Teva Pharmaceutical Completes Public Offering Of Senior Notes For $5 Billion 10
2.2.4 Express Scripts Completes Private Placement Of Senior Notes For $4.1 Billion 11
2.2.5 Lundbeck Enters Into Co-Development Agreement With Otsuka Pharmaceutical 11
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Values, November 2011 12
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13
3.1 Pharmaceuticals and Healthcare, Global, MandA, November 2011 13
3.1.1 Top MandA Deals in November 2011 14
3.1.2 Pharmaceuticals and Healthcare, Global, MandA Deals by Therapy Area, June 2011-November 2011 15
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, November 2011 16
3.2.1 Top Equity Offering Deals in November 2011 17
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, June 2011 - November 2011 18
3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, November 2011 19
3.3.1 Top Debt Offering Deals in November 2011 20
3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, June 2011 - November 2011 21
3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, November 2011 22
3.4.1 Top PE/VC Deals in November 2011 23
3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, November 2011 24
3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2011 25
3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, June 2011 - November 2011 26
3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, November 2011 28
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, November 2011 28
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, June 2011 - November 2011 29
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 30
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, November 2011 31
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 33
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, November 2011 35
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, November 2011 35
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 36
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, November 2011 37
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2011 37
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2011 38
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2011 - November 2011 39
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 40
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2011 - November 2011 41
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2011 - November 2011 42
6 Pharmaceuticals and Healthcare, Global, Deal Summary by Therapy Area 43
6.1 Pharmaceuticals and Healthcare, Global, Oncology Deals, November 2011 43
6.1.1 Oncology - Deals of the Month 44
6.2 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, November 2011 46
6.2.1 Infectious Diseases - Deals of the Month 47
6.3 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, November 2011 48
6.3.1 Central Nervous System - Deals of the Month 49
6.4 Pharmaceuticals and Healthcare, Global, Metabolic Disorder Deals, November 2011 50
6.4.1 Metabolic Disorders - Deals of the Month 51
6.5 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, November 2011 52
6.5.1 Cardiovascular - Deals of the Month 53
6.6 Pharmaceuticals and Healthcare, Global, Immunology Deals, November 2011 54
6.6.1 Immunology - Deals of the Month 55
6.7 Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals, November 2011 56
6.7.1 Gastrointestinal - Deals of the Month 57
7 Deal Summary by Geography 58
7.1 Pharmaceuticals and Healthcare, North America Deals, November 2011 58
7.1.1 North America - Deals of the Month 59
7.2 Pharmaceuticals and Healthcare, Europe, Deals, November 2011 60
7.2.1 Europe - Deals of the Month 61
7.3 Pharmaceuticals and Healthcare, Asia-Pacific, Regional Deals, November 2011 62
7.3.1 Asia-Pacific - Deals of the Month 63
7.4 Pharmaceuticals and Healthcare, Rest of the World, Deals, November 2011 64
7.4.1 Rest of the World - Deals of the Month 65
8 Pharmaceuticals and Healthcare, Global, Top Financial Advisors 66
8.1 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, June 2011 - November 2011 66
8.2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2011 - November 2011 67
9 Further Information 68
9.1 Methodology 68
9.2 About GlobalData 68
9.3 Contact Us 69
9.4 Disclosure information 69
9.5 Disclaimer 69

List of Tables


Table 1: Pharmaceuticals and Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 9
Table 2: Pharmaceuticals and Healthcare, Global, Top Deals, November 2011 10
Table 3: Pharmaceuticals and Healthcare, Global, Number Of Deals and Deal Values (%), November 2011 12
Table 4: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Table 5: Pharmaceuticals and Healthcare, Global, Top MandA Deals, November 2011 14
Table 6: Pharmaceuticals and Healthcare, Global, MandA, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Table 7: Pharmaceuticals and Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Table 8: Pharmaceuticals and Healthcare, Global, Top Equity Offering Deals, November 2011 17
Table 9: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Table 10: Pharmaceuticals and Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Table 11: Pharmaceuticals and Healthcare, Global, Top Debt Offering Deals, November 2011 20
Table 12: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), June 2011 - November 2011 21
Table 13: Pharmaceuticals and Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Table 14: Pharmaceuticals and Healthcare, Global, Top PE/VC Deals, November 2011 23
Table 15: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2011 - November 2011 24
Table 16: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2011 25
Table 17: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Table 18: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, June 2011 - November 2011 27
Table 19: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Table 20: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Table 21: Pharmaceuticals and Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Table 22: Pharmaceuticals and Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2011 31
Table 23: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Table 24: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Table 25: Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2011 - November 2011 34
Table 26: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Table 27: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Table 28: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Deal Value, November 2011 37
Table 29: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, September 2011 37
Table 30: Pharmaceuticals and Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, September 2011 38
Table 31: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), June 2011 - November 2011 39
Table 32: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2011 40
Table 33: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, June 2011 - November 2011 41
Table 34: Pharmaceuticals and Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Table 35: Pharmaceuticals and Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 44
Table 36: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Table 37: Pharmaceuticals and Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Table 38: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 51
Table 39: Pharmaceuticals and Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Table 40: Pharmaceuticals and Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Table 41: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Table 42: Pharmaceuticals and Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 59
Table 43: Pharmaceuticals and Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Table 44: Pharmaceuticals and Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Table 45: Pharmaceuticals and Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Table 46: Pharmaceuticals and Healthcare, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Table 47: Pharmaceuticals and Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

List of Figures


Figure 1: Pharmaceuticals and Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 8
Figure 2: Pharmaceuticals and Healthcare, Global, Number Of Deals (%) and Deal Values (%),November 2011 12
Figure 3: Pharmaceuticals and Healthcare, Global, MandA, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 13
Figure 4: Pharmaceuticals and Healthcare, Global, MandAs by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 15
Figure 5: Pharmaceuticals and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 16
Figure 6: Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 18
Figure 7: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 19
Figure 8: Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 21
Figure 9: Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 22
Figure 10: Pharmaceuticals and Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2011 - November 2011 24
Figure 11: Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), November 2011 25
Figure 12: Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 26
Figure 13: Pharmaceuticals and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 28
Figure 14: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 29
Figure 15: Pharmaceuticals and Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 30
Figure 16: Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 32
Figure 17: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, June 2011 - November 2011 33
Figure 18: Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 34
Figure 19: Pharmaceuticals and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 35
Figure 20: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 36
Figure 21: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 39
Figure 22: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2011 - November 2011 40
Figure 23: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), June 2011 - November 2011 41
Figure 24: Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2011 42
Figure 25: Pharmaceuticals and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 43
Figure 26: Pharmaceuticals and Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 46
Figure 27: Pharmaceuticals and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 48
Figure 28: Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 50
Figure 29: Pharmaceuticals and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 52
Figure 30: Pharmaceuticals and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 54
Figure 31: Pharmaceuticals and Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 56
Figure 32: Pharmaceuticals and Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 58
Figure 33: Pharmaceuticals and Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 60
Figure 34: Pharmaceuticals and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 62
Figure 35: Pharmaceuticals and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 64
Figure 36: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, MandA, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 66
Figure 37: Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2011 - November 2011 67

Companies mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Vertical-Cavity Surface-Emitting Lasers (VCSEL) : Technologies and Global Markets

Vertical-Cavity Surface-Emitting Lasers (VCSEL) : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

The use of vertical-cavity surface-emitting lasers (VCSELs) has increased in the optical communications industry in the past 15 years. This spurring demand can be attributed to the increasing demand of ...

Merger and Acquisition Trends in the Global Food and Beverage Industry

Merger and Acquisition Trends in the Global Food and Beverage Industry

  • $ 6 000
  • Industry report
  • May 2014
  • by Frost & Sullivan

Average Deal Values are on the Rise This study analyzes the merger and acquisition (M&A) transactions that have taken place in the global food and beverage industry between January 2007 and December 2013. ...

Workflow Management System Market by Workflow System Types (Production, Messaging-based, Web-based, Suite-based, Others), Users (SMBs, Enterprises), Deployment Model (Cloud, On-premise) - Market Forecasts and Analysis (2014-2019)

Workflow Management System Market by Workflow System Types (Production, Messaging-based, Web-based, Suite-based, Others), Users (SMBs, Enterprises), Deployment Model (Cloud, On-premise) - Market Forecasts and Analysis (2014-2019)

  • $ 4 650
  • Industry report
  • May 2014
  • by MarketsandMarkets

Workflow management systems comprise information management, document management, automation of work procedures, comprehensive conceptualization, and model building of business operations. Workflow management ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.